TENX · Tenax Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| ADAR1 Capital Management, LLC 10% Owner | ▲ Buy | Open Market | 6,524,151 Shares held | 9/3/2026 | View profile |
| Doogan Declan | ▲ Buy | Open Market | 55,274 Shares held | 9/16/2026 | View profile |
| Giordano Christopher Thomas CEO | ▲ Buy | Open Market | 22,174 Shares held | 9/15/2026 | View profile |
| Thomas R. Staab II Chief Financial Officer | ▲ Buy | Open Market | 15,675 Shares held | 9/11/2026 | View profile |
| Rich Stuart Chief Medical Officer | ▲ Buy | Open Market | 5,266 Shares held | 12/9/2025 | View profile |
| MCGAULEY THOMAS Interim CFO | ▲ Buy | Open Market | 5,000 Shares held | 11/17/2025 | View profile |
| Michael H. Davidson Chief Executive Officer | ▲ Buy | Open Market | 2,881 Shares held | 8/8/2024 | View profile |
| Almenoff June Sherie Director | ▲ Buy | Open Market | 1,993 Shares held | 11/18/2025 | View profile |
| Gerald T. Proehl President, CEO and Chairman | ▲ Buy | Open Market | 1,667 Shares held | 8/8/2024 | View profile |
Transaction History
| Doogan Declan | ▲ Buy | Open Market | 53,000 | $102K | 9/16/2026 |
| Giordano Christopher Thomas | ▲ Buy | Open Market | 4,850 | $9K | 9/15/2026 |
| Giordano Christopher Thomas | ▲ Buy | Open Market | 6,000 | $11K | 9/11/2026 |
| Thomas R. Staab II | ▲ Buy | Open Market | 5,675 | $11K | 9/11/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 900,000 | $1.6M | 9/3/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 187,704 | $338K | 9/2/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 179,058 | $322K | 9/1/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 403,571 | $723K | 8/31/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 107,374 | $188K | 8/24/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 716,369 | $1.3M | 8/21/2026 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 202,124 | $360K | 8/20/2026 |
| Giordano Christopher Thomas | ▲ Buy | Option Exercise | 219 | $777 | 7/13/2026 |
| Giordano Christopher Thomas | ▲ Buy | Option Exercise | 8,500 | $50K | 7/13/2026 |
| Thomas R. Staab II | ▲ Buy | Grant | 10,000 | $0 | 5/11/2026 |
| Rich Stuart | ▲ Buy | Open Market | 2,500 | $26K | 12/9/2025 |
| Rich Stuart | ▲ Buy | Open Market | 2,500 | $25K | 12/8/2025 |
| Rich Stuart | ▲ Buy | Open Market | 2,500 | $23K | 12/4/2025 |
| Rich Stuart | ▲ Buy | Open Market | 1,500 | $14K | 12/3/2025 |
| Rich Stuart | ▲ Buy | Open Market | 1,000 | $9K | 12/2/2025 |
| Giordano Christopher Thomas | ▲ Buy | Open Market | 538 | $4K | 11/20/2025 |
| Giordano Christopher Thomas | ▲ Buy | Open Market | 455 | $3K | 11/19/2025 |
| Giordano Christopher Thomas | ▲ Buy | Open Market | 1,612 | $13K | 11/18/2025 |
| Almenoff June Sherie | ▲ Buy | Open Market | 1,900 | $14K | 11/18/2025 |
| MCGAULEY THOMAS | ▲ Buy | Open Market | 2,000 | $15K | 11/17/2025 |
| MCGAULEY THOMAS | ▲ Buy | Open Market | 1,000 | $7K | 11/17/2025 |
| MCGAULEY THOMAS | ▲ Buy | Open Market | 5,000 | $36K | 11/17/2025 |
| Almenoff June Sherie | ▲ Buy | Open Market | 93 | $665 | 11/17/2025 |
| Michael H. Davidson | ▲ Buy | Open Market | 2,500 | — | 8/8/2024 |
| Gerald T. Proehl | ▲ Buy | Open Market | 1,666 | — | 8/8/2024 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 9/21/2022 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 9/21/2022 |
| Doogan Declan | ▼ Sell | Gift | 567,871 | $0 | 8/11/2022 |
| Doogan Declan | ▼ Sell | Gift | 567,871 | $0 | 8/11/2022 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 11/29/2021 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 11/29/2021 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 10/12/2021 |
| Rich Stuart | ▼ Sell | Gift | 1,909,585 | $0 | 10/12/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.